-

Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva Pharmaceuticals

  • Medincell to receive a $5 million development milestone payment from Teva with SOLARIS study completion (last patient last visit)
  • Richard Malamut, Chief Medical Officer at Medincell comments: “Our partner is advancing the clinical development of the olanzapine LAI with plans for regulatory submission in the US. This structured approach highlights a strong commitment to addressing a critical unmet need. As a result of Medincell technology, a long-acting injectable formulation of olanzapine may be widely used by patients with schizophrenia.”

MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Paris:MEDCL):

ACCESS HERE THE FULL PRESS RELEASE

Contacts

David Heuzé
Head of Corporate and Financial Communications, and ESG
david.heuze@Medincell.com / +33 (0)6 83 25 21 86

Grace Kim
Head of US Financial Strategy & IR
grace.kim@Medincell.com / +1 (646) 991-4023

Nicolas Mérigeau/ Arthur Rouillé
Media Relations
Medincell@newcap.eu / +33 (0)1 44 71 94 94

Louis-Victor Delouvrier/Alban Dufumier
Investor Relations France
Medincell@newcap.eu / +33 (0)1 44 71 94 94

Industry:

Medincell

BOURSE:MEDCL
Release Versions
English

Contacts

David Heuzé
Head of Corporate and Financial Communications, and ESG
david.heuze@Medincell.com / +33 (0)6 83 25 21 86

Grace Kim
Head of US Financial Strategy & IR
grace.kim@Medincell.com / +1 (646) 991-4023

Nicolas Mérigeau/ Arthur Rouillé
Media Relations
Medincell@newcap.eu / +33 (0)1 44 71 94 94

Louis-Victor Delouvrier/Alban Dufumier
Investor Relations France
Medincell@newcap.eu / +33 (0)1 44 71 94 94

More News From Medincell

Medincell to Participate in Upcoming Investor Conferences

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced its participation in the following September 2026 investor conferences by Dr Grace Kim, Chief Strategy Officer, U.S. Finance. Meetings may be scheduled with conference coordinators or directly with Medincell. Morgan Stanley 24th Annual Global Healthcare Conference: Monday Septe...

Medincell to Participate in Upcoming Investor Conferences

MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced its participation in the following September 2026 investor conferences by Dr Grace Kim, Chief Strategy Officer, U.S. Finance. Meetings may be scheduled with conference coordinators or directly with Medincell. Morgan Stanley 24th Annual Global Healthcare Conference: Monday September 14, 2026 – W...

Medincell: Publication of the Notice of Meeting and Reminder of the Participation terms in the Combined General Meeting

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL): The Annual General Meeting and Extraordinary General Meeting will be held at Medincell’s headquarters (3 rue des Frères Lumière, 34830 Jacou, France) on Wednesday, September 30, 2026, at 6:00 p.m. CEST. The notice was published in the “BALO” (French): https://www.journal-officiel.gouv.fr/telechargements/BALO/pdf/2026/0826/202608262603475.pdf The resolutions proposed for voting at the General Assembly include: Approv...
Back to Newsroom